BR112016029612A2 - compostos de di-hidroisoquinolinona substituídos - Google Patents
compostos de di-hidroisoquinolinona substituídosInfo
- Publication number
- BR112016029612A2 BR112016029612A2 BR112016029612A BR112016029612A BR112016029612A2 BR 112016029612 A2 BR112016029612 A2 BR 112016029612A2 BR 112016029612 A BR112016029612 A BR 112016029612A BR 112016029612 A BR112016029612 A BR 112016029612A BR 112016029612 A2 BR112016029612 A2 BR 112016029612A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- salts
- substituted
- substituted dihydroisoquinolinone
- dihydroisoquinolinone compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
esta invenção refere-se aos compostos de fórmula geral (i) (i), em que r1, r2, r3, r4, l, x e z são como definidos aqui, e os sais farmaceuticamente aceitáveis dos mesmos, às composições farmacêuticas compreendendo tais compostos e sais, e aos métodos de usar tais compostos, sais e composições para o tratamento de desenvolvimento celular anormal, incluindo câncer.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462013410P | 2014-06-17 | 2014-06-17 | |
US62/013,410 | 2014-06-17 | ||
US201562156533P | 2015-05-04 | 2015-05-04 | |
US62/156,533 | 2015-05-04 | ||
PCT/IB2015/054272 WO2015193765A1 (en) | 2014-06-17 | 2015-06-05 | Substituted dihydroisoquinolinone compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016029612A2 true BR112016029612A2 (pt) | 2017-08-22 |
BR112016029612B1 BR112016029612B1 (pt) | 2021-01-19 |
Family
ID=53434412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016029612-5A BR112016029612B1 (pt) | 2014-06-17 | 2015-06-05 | compostos de di-hidroisoquinolinona substituídos |
Country Status (40)
Country | Link |
---|---|
US (4) | US9481666B2 (pt) |
EP (2) | EP3157915B1 (pt) |
JP (1) | JP6152495B1 (pt) |
KR (1) | KR101877187B1 (pt) |
CN (1) | CN107207464B (pt) |
AP (1) | AP2016009605A0 (pt) |
AU (1) | AU2015275826B2 (pt) |
BR (1) | BR112016029612B1 (pt) |
CA (1) | CA2894298C (pt) |
CL (1) | CL2016003246A1 (pt) |
CR (2) | CR20160574A (pt) |
CU (1) | CU24408B1 (pt) |
CY (1) | CY1121706T1 (pt) |
DK (1) | DK3157915T3 (pt) |
EA (1) | EA031892B1 (pt) |
ES (1) | ES2721031T3 (pt) |
GE (1) | GEP20186933B (pt) |
HR (1) | HRP20190604T1 (pt) |
HU (1) | HUE042964T2 (pt) |
IL (1) | IL248991B (pt) |
LT (1) | LT3157915T (pt) |
MA (1) | MA40225B1 (pt) |
MD (1) | MD4820C1 (pt) |
ME (1) | ME03419B (pt) |
MX (1) | MX2016016764A (pt) |
MY (1) | MY185765A (pt) |
NZ (1) | NZ726108A (pt) |
PE (1) | PE20161552A1 (pt) |
PH (1) | PH12016502378A1 (pt) |
PL (1) | PL3157915T3 (pt) |
PT (1) | PT3157915T (pt) |
RS (1) | RS58632B1 (pt) |
SG (1) | SG11201609386YA (pt) |
SI (1) | SI3157915T1 (pt) |
SV (1) | SV2016005333A (pt) |
TN (1) | TN2016000529A1 (pt) |
TW (1) | TWI561516B (pt) |
UA (1) | UA118380C2 (pt) |
UY (1) | UY36170A (pt) |
WO (1) | WO2015193765A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
TN2016000529A1 (en) | 2014-06-17 | 2018-04-04 | Pfizer | Substituted dihydroisoquinolinone compounds |
TW201708210A (zh) * | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產(第二)有限公司 | Zeste同源物2增強子之抑制劑 |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
EP3452483B1 (en) | 2016-05-05 | 2020-04-01 | GlaxoSmithKline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
WO2019016112A1 (en) | 2017-07-17 | 2019-01-24 | AbbVie Deutschland GmbH & Co. KG | SUBSTITUTED QUINOLINE COMPOUNDS IN POSITIONS 1, 2, 3 AND 4 AS MODULATORS OF S1P |
WO2019097369A1 (en) * | 2017-11-14 | 2019-05-23 | Pfizer Inc. | Ezh2 inhibitor combination therapies |
JP7025556B2 (ja) | 2018-01-31 | 2022-02-24 | ミラティ セラピューティクス, インコーポレイテッド | Prc2阻害剤 |
EP3781561B1 (en) | 2018-04-18 | 2024-03-13 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP3797108B1 (en) * | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CN112399857A (zh) | 2018-07-09 | 2021-02-23 | 盲人庇护基金会 | Prc2亚单位的抑制治疗眼失调 |
EP3870173A4 (en) * | 2018-10-24 | 2022-06-22 | Vanderbilt University | WDR5 MODULATORS AND INHIBITORS |
KR20200101219A (ko) * | 2019-02-19 | 2020-08-27 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
WO2022018594A1 (en) | 2020-07-20 | 2022-01-27 | Pfizer Inc. | Synthesis of novel intermediates for substituted 3,4-dihydroisoquinolinones |
EP4261211A1 (en) * | 2020-12-11 | 2023-10-18 | Etern Biopharma (Shanghai) Co., Ltd. | Dihydroisoquinolinone derivative and application thereof |
WO2023098880A1 (zh) * | 2021-12-02 | 2023-06-08 | 上海翰森生物医药科技有限公司 | 稠环类衍生物调节剂、其制备方法和应用 |
WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3846412A (en) | 1971-03-18 | 1974-11-05 | Lepetit Spa | Dihydro-2-amino-isoquinolines and their derivatives |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
US20070093515A1 (en) | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
JP2009524589A (ja) * | 2005-12-22 | 2009-07-02 | ワイス | 置換されたイソキノリン−1,3(2h,4h)−ジオン、1−チオキソ−1,4−ジヒドロ−2h−イソキノリン−3−オン誘導体、および1,4−ジヒドロ−3(2h)−イソキノロン、ならびにキナーゼインヒビターとしてのそれらの使用 |
US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
EP2303861B1 (en) * | 2008-06-17 | 2014-04-23 | AstraZeneca AB | Pyridine compounds |
US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
WO2011103016A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
EP2566479B1 (en) | 2010-05-07 | 2014-12-24 | GlaxoSmithKline LLC | Azaindazoles |
PL2566327T3 (pl) | 2010-05-07 | 2017-09-29 | Glaxosmithkline Llc | Indole |
WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
DK2614369T3 (en) | 2010-09-10 | 2016-05-02 | Epizyme Inc | METHOD FOR DETERMINING THE SUITABILITY OF HUMAN EZH2 INHIBITORS TREATED |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
CA2850570A1 (en) | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
WO2013059944A1 (en) * | 2011-10-28 | 2013-05-02 | British Columbia Cancer Agency Branch | Epigenetic regulators and uses thereof |
US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
CA2884848C (en) | 2012-09-28 | 2017-08-22 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
UA111305C2 (uk) * | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
EA201590943A1 (ru) | 2012-12-21 | 2016-01-29 | Алиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
SG11201504754QA (en) | 2012-12-21 | 2015-07-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
FR3000059A1 (fr) | 2012-12-21 | 2014-06-27 | Saint Gobain Placo | Composition pour plaques de platre et produits obtenus |
SI2934567T1 (sl) | 2012-12-21 | 2018-10-30 | Sanofi | Derivati eksendina-4 kot dualni GLP1/GIP ali trigonalni agonisti GLP1/GIP/glukagon |
PT2822954E (pt) | 2012-12-21 | 2016-06-16 | Gilead Sciences Inc | Compostos carbamoilpiridona policíclicos e seu uso farmacêutico |
UA118548C2 (uk) | 2012-12-21 | 2019-02-11 | Епізайм, Інк. | Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування |
FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
PL2935312T3 (pl) | 2012-12-21 | 2018-12-31 | F.Hoffmann-La Roche Ag | Peptydy jako agoniści oksytocyny |
TN2016000529A1 (en) | 2014-06-17 | 2018-04-04 | Pfizer | Substituted dihydroisoquinolinone compounds |
-
2015
- 2015-06-05 TN TN2016000529A patent/TN2016000529A1/en unknown
- 2015-06-05 MX MX2016016764A patent/MX2016016764A/es active IP Right Grant
- 2015-06-05 AU AU2015275826A patent/AU2015275826B2/en active Active
- 2015-06-05 GE GEAP201514347A patent/GEP20186933B/en unknown
- 2015-06-05 PT PT15730290T patent/PT3157915T/pt unknown
- 2015-06-05 CN CN201580032058.7A patent/CN107207464B/zh active Active
- 2015-06-05 KR KR1020177001230A patent/KR101877187B1/ko active IP Right Grant
- 2015-06-05 PE PE2016002737A patent/PE20161552A1/es unknown
- 2015-06-05 SG SG11201609386YA patent/SG11201609386YA/en unknown
- 2015-06-05 CR CR20160574A patent/CR20160574A/es unknown
- 2015-06-05 AP AP2016009605A patent/AP2016009605A0/en unknown
- 2015-06-05 WO PCT/IB2015/054272 patent/WO2015193765A1/en active Application Filing
- 2015-06-05 EP EP15730290.2A patent/EP3157915B1/en active Active
- 2015-06-05 EA EA201692114A patent/EA031892B1/ru unknown
- 2015-06-05 HU HUE15730290A patent/HUE042964T2/hu unknown
- 2015-06-05 EP EP19159058.7A patent/EP3521285A1/en not_active Withdrawn
- 2015-06-05 ME MEP-2019-85A patent/ME03419B/me unknown
- 2015-06-05 ES ES15730290T patent/ES2721031T3/es active Active
- 2015-06-05 BR BR112016029612-5A patent/BR112016029612B1/pt active IP Right Grant
- 2015-06-05 LT LTEP15730290.2T patent/LT3157915T/lt unknown
- 2015-06-05 MY MYPI2016704453A patent/MY185765A/en unknown
- 2015-06-05 PL PL15730290T patent/PL3157915T3/pl unknown
- 2015-06-05 CR CR20200484A patent/CR20200484A/es unknown
- 2015-06-05 CU CU2016000180A patent/CU24408B1/es unknown
- 2015-06-05 RS RS20190512A patent/RS58632B1/sr unknown
- 2015-06-05 MD MDA20160136A patent/MD4820C1/ro active IP Right Grant
- 2015-06-05 UA UAA201611695A patent/UA118380C2/uk unknown
- 2015-06-05 JP JP2016573051A patent/JP6152495B1/ja active Active
- 2015-06-05 DK DK15730290.2T patent/DK3157915T3/en active
- 2015-06-05 NZ NZ726108A patent/NZ726108A/en unknown
- 2015-06-05 MA MA40225A patent/MA40225B1/fr unknown
- 2015-06-05 SI SI201530698T patent/SI3157915T1/sl unknown
- 2015-06-15 TW TW104119287A patent/TWI561516B/zh active
- 2015-06-16 UY UY0001036170A patent/UY36170A/es not_active Application Discontinuation
- 2015-06-16 CA CA2894298A patent/CA2894298C/en active Active
- 2015-06-16 US US14/740,439 patent/US9481666B2/en active Active
-
2016
- 2016-09-12 US US15/262,230 patent/US20160376254A1/en not_active Abandoned
- 2016-11-15 IL IL248991A patent/IL248991B/en active IP Right Grant
- 2016-11-29 PH PH12016502378A patent/PH12016502378A1/en unknown
- 2016-12-05 SV SV2016005333A patent/SV2016005333A/es unknown
- 2016-12-19 CL CL2016003246A patent/CL2016003246A1/es unknown
-
2017
- 2017-06-28 US US15/635,648 patent/US20170298048A1/en not_active Abandoned
-
2018
- 2018-10-10 US US16/156,304 patent/US10570121B2/en active Active
-
2019
- 2019-03-28 HR HRP20190604TT patent/HRP20190604T1/hr unknown
- 2019-04-05 CY CY20191100381T patent/CY1121706T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016029612A2 (pt) | compostos de di-hidroisoquinolinona substituídos | |
BR112018069612A2 (pt) | compostos de pirroltriazina como inibidores de tam | |
CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
NI201700096A (es) | Derivados de 4h-pirrol[3, 2-c]piridin-4-ona | |
BR112017010893A2 (pt) | análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos | |
BR112017009657A2 (pt) | análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos | |
EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
UY36733A (es) | Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
BR112015032595A2 (pt) | inibidores de ido | |
BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
BR112017026682A2 (pt) | novos compostos bicíclicos como inibidores de dupla ação de atx/ca | |
UY36737A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
CO2017001528A2 (es) | Compuestos novedosos de pirimidina sustituidos | |
BR112016002638A2 (pt) | novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório | |
BR112017023959A2 (pt) | novos compostos de sulfonimidoilpurinona e derivados para o tratamento e profilaxia de infecção por vírus | |
CO2017001506A2 (es) | Compuestos novedosos de pirimidina sustituidos | |
BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
BR112017023080A2 (pt) | compostos benzimidazolona e benzotiazolona e uso dos mesmos como moduladores do receptor de ampa | |
BR112014030474A2 (pt) | novos compostos bicíclicos de tiofenilamida | |
BR112016018418A2 (pt) | Composto, uso do mesmo, e composição farmacêutica | |
BR112016024513A2 (pt) | derivados de di-heterociclo ligados à cicloalquila |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/06/2015, OBSERVADAS AS CONDICOES LEGAIS. |
|
B25G | Requested change of headquarter approved |
Owner name: PFIZER INC. (US) |